Clinical Trials Browser

Phase 1 × Multiple Myeloma × Gemcitabine × Clear all

NCT00477035 2017-01-11

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Phase 1 Completed

Other hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma